Cat. No：GM-C20152
Product：H_LILRB3 Reporter Jurkat Cell Line
Cat. No：GM-C20152
Product：H_LILRB3 Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10%DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
The human leukocyte immunoglobulin-like receptor (LILR) family consists of 5 activating receptors (LILRA1-5), 6 inhibitory receptors (LILRB1-6), and two pseudogenes. Different receptors are expressed in lymphocytes and myeloid cells, influencing innate and adaptive immune functions.
Human LILRB3 (also known as CD85A, ILT5, LIR3, or HL9) contains 4 extracellular immunoglobulin domains, a transmembrane domain, and 4 cytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIMs). LILRB3 is expressed in monocytes, granulocytes, dendritic cells, osteoclasts, and macrophage progenitor cells, but its ligand remains unidentified. The potential applications of LILRB3 in immune dysregulation, including inflammatory diseases, autoimmune conditions, and cancer therapy, are promising.
The H_LILRB3 Reporter Jurkat Cell Line from Genomeditech contains a reporter gene that, when activated by ligands or antibody agonists binding to LILRB3, initiates the CD3ζ cascade, activating the expression of luciferase. This cell model can be used for screening ligands and antibody agonists.
Cat. No：GM-C20152
Product：H_LILRB3 Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10%DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
The human leukocyte immunoglobulin-like receptor (LILR) family consists of 5 activating receptors (LILRA1-5), 6 inhibitory receptors (LILRB1-6), and two pseudogenes. Different receptors are expressed in lymphocytes and myeloid cells, influencing innate and adaptive immune functions.
Human LILRB3 (also known as CD85A, ILT5, LIR3, or HL9) contains 4 extracellular immunoglobulin domains, a transmembrane domain, and 4 cytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIMs). LILRB3 is expressed in monocytes, granulocytes, dendritic cells, osteoclasts, and macrophage progenitor cells, but its ligand remains unidentified. The potential applications of LILRB3 in immune dysregulation, including inflammatory diseases, autoimmune conditions, and cancer therapy, are promising.
The H_LILRB3 Reporter Jurkat Cell Line from Genomeditech contains a reporter gene that, when activated by ligands or antibody agonists binding to LILRB3, initiates the CD3ζ cascade, activating the expression of luciferase. This cell model can be used for screening ligands and antibody agonists.
